MIRANDA POLLMAN: Open Payments
NPI 1558856898 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$921 in 47 payments from 14 companies in 2025. Trend: 2023 $971 · 2024 $1,315 · 2025 $921
Food & beverage: $921
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $239 |
| AstraZeneca Pharmaceuticals LP | 5 | $186 |
| Novo Nordisk Inc | 7 | $120 |
| PFIZER INC. | 5 | $81 |
| Abbott Laboratories | 2 | $46 |
| Lilly USA, LLC | 3 | $42 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $37 |
| Dexcom, Inc. | 2 | $35 |
| Boston Scientific Corporation | 1 | $35 |
| Corcept Therapeutics | 2 | $28 |
Products named: VRAYLAR, FARXIGA, Wegovy, NURTEC ODT, AIRSUPRA, UBRELVY, FREESTYLE LIBRE 3, CAPLYTA.
Industry payments across NE — which companies pay providers there.
